Navigation Links
Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
Date:3/11/2013

TOKYO and SAN DIEGO, March 12, 2013 /PRNewswire/ -- Astellas Pharma Inc. (Astellas) (Tokyo: 4503) and Ambit Biosciences Corporation today announced the companies will end their collaboration for the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, including quizartinib, effective September 3, 2013. Astellas has exercised its right to terminate the worldwide license agreement signed in 2009, and over the months ahead the companies will work together to transfer current development activities to Ambit. Upon the effective date of termination, Ambit will regain all rights granted to Astellas and continue with the quizartinib clinical trial program.

"While our decision is based on strategic reasons, we are proud of our collaborative work with Ambit, and we are committed to working with Ambit on a smooth transition," said Yoshihiko Hatanaka , President and CEO of Astellas. "We remain committed to the field of Oncology as a major area of focus for the company and will continue to pursue our goal of becoming a Global Category Leader in Oncology." 

Michael Martino , President and CEO of Ambit, said, "With the Phase 2 study results for quizartinib that were presented at the ASH Annual Meeting last December, we and members of the medical community continue to be excited about quizartinib and its potential to meet a significant, unmet need in acute myeloid leukemia (AML) patients. We are fully committed to moving forward with the Phase 3 clinical trial plan and look forward to advancing this important drug candidate toward approval."

About QuizartinibQuizartinib (AC220) is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently under evaluation in a Phase 2b clinical trial as monotherapy treatment for adult patients
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
2. Astellas to Drive PGA TOURs New Womens Initiative
3. Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
6. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
7. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
8. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
9. First sales of DIFICLIRâ„¢ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
10. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
11. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 P&S Market ... market overview, trends, DRO analysis, market segmentation, ... developments, competitive scenario and top competitor profiles ... Market Development and Demand Forecast to 2020  ... Explore more about global biosensors ...
(Date:7/30/2015)... , July 30, 2015   Gaumard® Scientific ... to UNI®, the world,s first operating system to ... now available exclusively to Gaumard users. UNI® version ... launched Newborn Tory™ S2200, as well as improvements ... of clinical measures such as EtCO 2 .  ...
(Date:7/30/2015)... VIEJO, Calif. , July 30, 2015 /PRNewswire/ ... aspiring to eliminate all preventable hospitalization, recently received ... that its Remote Patient Intelligence (RPI) solution meets ... the FDA intends to exercise "Enforcement Discretion." ... "are not subject to further FDA regulatory requirements ...
Breaking Medicine Technology:Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3
(Date:7/31/2015)... FL (PRWEB) , ... July 31, 2015 , ... Like ... enlargement techniques have also been advanced, upgraded, made more effective and less intrusive and ... of Loria Medical Penile Enlargement Center. Dr. Loria currently stands as the only ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Heart Fit Clinic has increased ... until a heart rate of 150 beats versus 100 beats, this is a big ... able to give life back to patients with heart disease," he adds. People with ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... a blog post that encourages the understanding and treatment of ankle sprains. A ... for in-home remedies. This can be dangerous if the condition augments and causes ...
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair ... that they are the latest recipients of the Center of Clinical Excellence for ... the worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration ...
(Date:7/31/2015)... Detroit, MI (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable ... The U.S. Women's National Soccer Team will face the Australia Women's National Team in conjunction ... by a score of 5-2. Carli Lloyd from the USA team was awarded the ...
Breaking Medicine News(10 mins):Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2
... , Got Moving Stories? Calling all Reporters, Writers, ... Aug. 5 The American Academy of Orthopaedic Surgeons ... MORE Awards . These awards recognize excellence in ... of bones, joints and muscles. The AAOS invites all journalists to ...
... , , CINCINNATI, Aug. ... (Nasdaq: STRM ) today announced that, in an effort ... have an independent, non-management director as the Company,s Chairman of the ... Phillips, a current independent member of the Company,s Board of Directors, ...
... ... Jacobson & Han LLP, internationally recognized immigration attorneys, offers on-site ... immigration worksite enforcement and new federal mandates. The current immigration ... need to become aware of how these challenges affect their business ...
... , , , , ... for the Prevention and Treatment of Cancer-Related Infections to include ... The NCCN Guidelines provide specific recommendations on the prevention, diagnosis, ... afflict patients with cancer , , FORT ...
... , , , ... S.C., and Carolinas HealthCare System (CHS) have executed an Affiliation Services ... Executives in attendance included CHS President and Chief Operating Officer Joe ... Officer John Miller. , , The ...
... , , , ... Effient(TM) (prasugrel), a new antiplatelet medicine, is now available in pharmacies ... Company (NYSE: LLY ) announced today. , ... Effient tablets on July 10 for the reduction of thrombotic cardiovascular ...
Cached Medicine News:Health News:MORE (Media Orthopaedic Reporting Excellence) Awards Call for Entries is Now Open 2Health News:MORE (Media Orthopaedic Reporting Excellence) Awards Call for Entries is Now Open 3Health News:Streamline Health Appoints Jon Phillips Chairman of the Board of Directors 2Health News:Streamline Health Appoints Jon Phillips Chairman of the Board of Directors 3Health News:Streamline Health Appoints Jon Phillips Chairman of the Board of Directors 4Health News:Streamline Health Appoints Jon Phillips Chairman of the Board of Directors 5Health News:Immigration Attorneys Make Immigration Law & Employment Visas Easier for Foreign Workers, U.S. Employers, Corporations and Corporate Counsel 2Health News:Immigration Attorneys Make Immigration Law & Employment Visas Easier for Foreign Workers, U.S. Employers, Corporations and Corporate Counsel 3Health News:Immigration Attorneys Make Immigration Law & Employment Visas Easier for Foreign Workers, U.S. Employers, Corporations and Corporate Counsel 4Health News:Immigration Attorneys Make Immigration Law & Employment Visas Easier for Foreign Workers, U.S. Employers, Corporations and Corporate Counsel 5Health News:NCCN Updates Infection Guidelines to Include Information About H1N1 Virus (Swine Flu) 2Health News:NCCN Updates Infection Guidelines to Include Information About H1N1 Virus (Swine Flu) 3Health News:South Carolina-Based AnMed Health Selects CHS for Affiliation Agreement 2Health News:South Carolina-Based AnMed Health Selects CHS for Affiliation Agreement 3Health News:Effient(TM) is Now Available in Pharmacies 2Health News:Effient(TM) is Now Available in Pharmacies 3Health News:Effient(TM) is Now Available in Pharmacies 4
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... With membrane parasite ... and cytoplasm as antigen. ... different antigens than the ... possible to use two ...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
Silicone ICD lead...
Medicine Products: